Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Abacavir Monotherapy in ART-Naive HIV
NCT00002390Phase 2Completed
- Sponsor
- GSK
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of abacavir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by GSK. Primary endpoints: HIV-1 RNA Level and CD4+ Cell Count. Status: completed.
02
Drugs
abacavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002390.